{
  "first_published_at": "2014-09-25", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON452540", 
  "title": "Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia—updated recommendations", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\", \"obstetrics-gynaecology-fertility\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\", \"Obstetrics, gynaecology and fertility\"]}", 
  "_document_number": 15, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer", 
    "obstetrics-gynaecology-fertility"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia&#8212;updated recommendations</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia. Before starting denosumab treatment, a dental examination and appropriate preventive dentistry are now recommended to reduce the risk of osteonecrosis of the jaw (ONJ). This applies to all patients considered for denosumab 120 mg for cancer and to patients with ONJ risk factors considered for denosumab 60 mg for osteoporosis (see below). Tell patients to maintain good oral hygiene and report any oral symptoms.</p>\n\n<p>The risk of hypocalcaemia increases with the degree of renal impairment. Monitor calcium levels depending on the indication as described below and tell patients to report symptoms of hypocalcaemia (see advice below)</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Denosumab 120 mg solution for injection (Xgeva&#9660;) is given once every 4 weeks to prevent skeletal related events (pathological fracture, radiation to bone, spinal cord compression, or surgery to bone) in adults with bone metastases from solid tumours.</p>\n\n<p>Denosumab 60 mg solution for injection (Prolia) is given once every 6 months to treat osteoporosis in postmenopausal women at increased risk of fractures. It is also indicated for treatment of bone loss associated with hormone ablation in men with prostate cancer who are at high risk of fractures.</p>\n\n<p><strong>Osteonecrosis of the jaw</strong></p>\n\n<p>Osteonecrosis of the jaw (ONJ) is a well-known and common side effect in patients receiving denosumab 120 mg for cancer. Risk factors for ONJ include:</p>\n\n<ul>\n<li>smoking</li>\n\n<li>old age</li>\n\n<li>poor oral hygiene</li>\n\n<li>invasive dental procedures (eg, tooth extractions, dental implants, oral surgery)</li>\n\n<li>comorbidity (eg, dental disease, anaemia, coagulopathy, infection)</li>\n\n<li>advanced cancer</li>\n\n<li>previous treatment with bisphosphonates</li>\n\n<li>concomitant treatments (eg, chemotherapy, antiangiogenic biologics, corticosteroids, radiotherapy to head and neck)</li>\n</ul>\n\n<p>In clinical trials, ONJ incidence increased with duration of denosumab 120 mg exposure. The patient-year adjusted incidence of confirmed ONJ was 1.1% in the first year of treatment, 3.7% in the second year, and 4.6% per year thereafter. Patients with certain dental risk factors (eg, history of ONJ, unhealed oral surgery) were excluded from these trials.</p>\n\n<p>There have been rare cases of ONJ in patients receiving denosumab 60 mg for osteoporosis in clinical practice. The most common risk factors were invasive dental procedures, history of bisphosphonate therapy, and being more than 65 years old.</p>\n\n<p>To date, we have received 9 Yellow Card reports<a id=\"_Ref394919824\" name=\"_Ref394919824\"> </a><a id=\"_ftnref1\" href=\"#_ftn1\" name=\"_ftnref1\" title=\"\"><span><span style=\" vertical-align: super;\">[1]</span></span></a> of ONJ in patients receiving denosumab 120 mg, 12 reports in patients receiving denosumab 60 mg, and 5 reports in patients receiving an unspecified dose of denosumab.</p>\n\n<p>Based on this evidence, the recommendations regarding the need for a dental examination and appropriate preventive dentistry before treatment have been updated as described below.</p>\n\n<p><strong>Hypocalcaemia</strong></p>\n\n<p>Denosumab is also associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment (see <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199560\" target=\"_blank\">Drug Safety Update article from October 2012</a>). Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later. Therefore the recommendations for calcium monitoring have been updated as described below.</p>\n\n<p>To date, we have received 23 Yellow Card reports<sup>1</sup> of hypocalcaemia in patients receiving denosumab 120 mg, 37 reports in patients receiving denosumab 60 mg, and 6 reports in patients receiving an unspecified dose of denosumab.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals</strong></p>\n\n<p><strong>Osteonecrosis of the jaw</strong></p>\n\n<p>The following precautions are now recommended to reduce the risk of ONJ:</p>\n\n<p>Denosumab 120 mg (cancer indication)</p>\n\n<ul>\n<li>A dental examination and appropriate preventive dentistry before starting denosumab 120 mg are now recommended for all patients.</li>\n\n<li>Do not start denosumab 120 mg in patients with a dental or jaw condition requiring surgery, or in patients who have not recovered following oral surgery.</li>\n</ul>\n\n<p>Denosumab 60 mg (osteoporosis indication)</p>\n\n<ul>\n<li>Check for ONJ risk factors before starting denosumab 60 mg. A dental examination and appropriate preventive dentistry are now recommended for patients with risk factors.</li>\n</ul>\n\n<p>Tell all patients to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.</p>\n\n<p><strong>Hypocalcaemia</strong></p>\n\n<p>Calcium levels should now be monitored as follows:</p>\n\n<p>Denosumab 120 mg (cancer indication)</p>\n\n<ul>\n<li>Check calcium levels: \n\n<ul>\n<li>before the first dose</li>\n\n<li>within two weeks after the initial dose</li>\n\n<li>if suspected symptoms of hypocalcaemia occur.</li>\n</ul>\n</li>\n</ul>\n\n<p>Consider monitoring calcium levels more frequently in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance &#60;30 ml/min).</p>\n\n<p>Denosumab 60 mg (osteoporosis indication)</p>\n\n<ul>\n<li>Check calcium levels: \n\n<ul>\n<li>before each dose</li>\n\n<li>within two weeks after the initial dose in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance &#60;30 ml/min)</li>\n\n<li>if suspected symptoms of hypocalcaemia occur.</li>\n</ul>\n</li>\n</ul>\n\n<p>Tell all patients to report symptoms of hypocalcaemia to their doctor (eg, muscle spasms, twitches, or cramps; numbness or tingling in the fingers, toes, or around the mouth).</p>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Letters to healthcare professionals sent in August 2014 &#8211; includes advice on ONJ and hypocalcaemia that was previously in the summary of product characteristics and has not been changed, as well as the new advice above</p>\n\n<p><a href=\"/home/groups/comms-ic/documents/drugsafetymessage/con454359.pdf\" target=\"_blank\">Denosumab 60 mg</a></p>\n\n<p><a href=\"/home/groups/comms-ic/documents/drugsafetymessage/con454360.pdf\" target=\"_blank\">Denosumab 120 mg</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 2, September 2014: A2</em></p>\n\n<div><br clear=\"all\" />\n<hr align=\"left\" size=\"1\" width=\"33%\" />\n<div id=\"ftn1\">\n<p style=\" margin: 0cm; margin-bottom: .0001pt; font-size: 10.0pt; font-family: 'Times New Roman', serif;\"><a id=\"_ftn1\" href=\"#_ftnref1\" name=\"_ftn1\" title=\"\"><span style=\" vertical-align: super;\"><span style=\" font-size: 8.0pt;\"><span><span style=\" font-size: 8.0pt; font-family: 'Times New Roman', serif;\">[1]</span></span></span></span></a><span style=\" font-size: 8.0pt; font-family: Arial,sans-serif;\">Yellow Card reports are reports of suspected adverse drug reactions (ADRs) submitted voluntarily by healthcare professionals and members of the public in the UK. The number of reports received should not be used to determine the incidence of an ADR. This is because neither the total number of ADRs occurring, nor the number of patients using the drug is known. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, and the extent of use of a particular drug, and may be stimulated by publicity about a drug.</span></p>\n</div>\n</div>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Denosumab 120 mg solution for injection (Xgeva&#9660;) is given once every 4 weeks to prevent skeletal related events (pathological fracture, radiation to bone, spinal cord compression, or surgery to bone) in adults with bone metastases from solid tumours.</p>\n\n<p>Denosumab 60 mg solution for injection (Prolia) is given once every 6 months to treat osteoporosis in postmenopausal women at increased risk of fractures. It is also indicated for treatment of bone loss associated with hormone ablation in men with prostate cancer who are at high risk of fractures.</p>\n\n<p><strong>Osteonecrosis of the jaw</strong></p>\n\n<p>Osteonecrosis of the jaw (ONJ) is a well-known and common side effect in patients receiving denosumab 120 mg for cancer. Risk factors for ONJ include:</p>\n\n<ul>\n<li>smoking</li>\n\n<li>old age</li>\n\n<li>poor oral hygiene</li>\n\n<li>invasive dental procedures (eg, tooth extractions, dental implants, oral surgery)</li>\n\n<li>comorbidity (eg, dental disease, anaemia, coagulopathy, infection)</li>\n\n<li>advanced cancer</li>\n\n<li>previous treatment with bisphosphonates</li>\n\n<li>concomitant treatments (eg, chemotherapy, antiangiogenic biologics, corticosteroids, radiotherapy to head and neck)</li>\n</ul>\n\n<p>In clinical trials, ONJ incidence increased with duration of denosumab 120 mg exposure. The patient-year adjusted incidence of confirmed ONJ was 1.1% in the first year of treatment, 3.7% in the second year, and 4.6% per year thereafter. Patients with certain dental risk factors (eg, history of ONJ, unhealed oral surgery) were excluded from these trials.</p>\n\n<p>There have been rare cases of ONJ in patients receiving denosumab 60 mg for osteoporosis in clinical practice. The most common risk factors were invasive dental procedures, history of bisphosphonate therapy, and being more than 65 years old.</p>\n\n<p>To date, we have received 9 Yellow Card reports<a id=\"_Ref394919824\" name=\"_Ref394919824\"></a><a id=\"_ftnref1\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON452540#_ftn1\" name=\"_ftnref1\" title=\"\">[1]<span><span style=\" vertical-align: super;\">[1]</span></span></a> of ONJ in patients receiving denosumab 120 mg, 12 reports in patients receiving denosumab 60 mg, and 5 reports in patients receiving an unspecified dose of denosumab.</p>\n\n<p>Based on this evidence, the recommendations regarding the need for a dental examination and appropriate preventive dentistry before treatment have been updated as described below.</p>\n\n<p><strong>Hypocalcaemia</strong></p>\n\n<p>Denosumab is also associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment (see <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199560\" target=\"_blank\">Drug Safety Update article from October 2012</a>). Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later. Therefore the recommendations for calcium monitoring have been updated as described below.</p>\n\n<p>To date, we have received 23 Yellow Card reports<sup>1</sup> of hypocalcaemia in patients receiving denosumab 120 mg, 37 reports in patients receiving denosumab 60 mg, and 6 reports in patients receiving an unspecified dose of denosumab.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals</strong></p>\n\n<p><strong>Osteonecrosis of the jaw</strong></p>\n\n<p>The following precautions are now recommended to reduce the risk of ONJ:</p>\n\n<p>Denosumab 120 mg (cancer indication)</p>\n\n<ul>\n<li>A dental examination and appropriate preventive dentistry before starting denosumab 120 mg are now recommended for all patients.</li>\n\n<li>Do not start denosumab 120 mg in patients with a dental or jaw condition requiring surgery, or in patients who have not recovered following oral surgery.</li>\n</ul>\n\n<p>Denosumab 60 mg (osteoporosis indication)</p>\n\n<ul>\n<li>Check for ONJ risk factors before starting denosumab 60 mg. A dental examination and appropriate preventive dentistry are now recommended for patients with risk factors.</li>\n</ul>\n\n<p>Tell all patients to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.</p>\n\n<p><strong>Hypocalcaemia</strong></p>\n\n<p>Calcium levels should now be monitored as follows:</p>\n\n<p>Denosumab 120 mg (cancer indication)</p>\n\n<ul>\n<li>Check calcium levels: \n\n<ul>\n<li>before the first dose</li>\n\n<li>within two weeks after the initial dose</li>\n\n<li>if suspected symptoms of hypocalcaemia occur.</li>\n</ul>\n</li>\n</ul>\n\n<p>Consider monitoring calcium levels more frequently in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance &lt;30 ml/min).</p>\n\n<p>Denosumab 60 mg (osteoporosis indication)</p>\n\n<ul>\n<li>Check calcium levels: \n\n<ul>\n<li>before each dose</li>\n\n<li>within two weeks after the initial dose in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance &lt;30 ml/min)</li>\n\n<li>if suspected symptoms of hypocalcaemia occur.</li>\n</ul>\n</li>\n</ul>\n\n<p>Tell all patients to report symptoms of hypocalcaemia to their doctor (eg, muscle spasms, twitches, or cramps; numbness or tingling in the fingers, toes, or around the mouth).</p>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Letters to healthcare professionals sent in August 2014 &#8211; includes advice on ONJ and hypocalcaemia that was previously in the summary of product characteristics and has not been changed, as well as the new advice above</p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454359.pdf\" target=\"_blank\">Denosumab 60 mg</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454360.pdf\" target=\"_blank\">Denosumab 120 mg</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 2, September 2014: A2</em></p>\n\n<div><br clear=\"all\">\n<hr align=\"left\" size=\"1\" width=\"33%\">\n<div id=\"ftn1\">\n<p style=\" margin: 0cm; margin-bottom: .0001pt; font-size: 10.0pt; font-family: 'Times New Roman', serif;\"><a id=\"_ftn1\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON452540#_ftnref1\" name=\"_ftn1\" title=\"\">[1]<span style=\" vertical-align: super;\"><span style=\" font-size: 8.0pt;\"><span><span style=\" font-size: 8.0pt; font-family: 'Times New Roman', serif;\">[1]</span></span></span></span></a><span style=\" font-size: 8.0pt; font-family: Arial,sans-serif;\">Yellow Card reports are reports of suspected adverse drug reactions (ADRs) submitted voluntarily by healthcare professionals and members of the public in the UK. The number of reports received should not be used to determine the incidence of an ADR. This is because neither the total number of ADRs occurring, nor the number of patients using the drug is known. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, and the extent of use of a particular drug, and may be stimulated by publicity about a drug.</span></p>\n</div>\n</div>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-09-01", 
  "date_last_modified": "2014-09-24", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Denosumab 60 mg", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454359.pdf", 
      "filename": "downloads/ed0edbbe01f33b4c98c2b89b2d6d794301d47a76/con454359.pdf", 
      "original_filename": "con454359.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Denosumab 120 mg", 
      "assetid": 1, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454360.pdf", 
      "filename": "downloads/19eae358e7cc15b62d9fffb1b35b6cdb7071c82b/con454360.pdf", 
      "original_filename": "con454360.pdf"
    }
  ], 
  "_item_id": 15, 
  "summary": "Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia. Before starting denosumab treatment, a dental examination and appropriate preventive dentistry are now recommended to reduce the risk of osteonecrosis of the jaw (ONJ). This applies to all patients considered for denosumab 120 mg for cancer and to patients with ONJ risk factors considered for denosumab 60 mg for osteoporosis (see below). Tell patients to maintain good oral hygiene and report any oral symptoms.\n\nThe risk of hypocalcaemia increases with the degree of renal impairment. Monitor calcium levels depending on the indication as described below and tell patients to report symptoms of hypocalcaemia (see advice below)", 
  "body": "Article date: September 2014\n\nDenosumab 120 mg solution for injection (Xgeva▼) is given once every 4 weeks to prevent skeletal related events (pathological fracture, radiation to bone, spinal cord compression, or surgery to bone) in adults with bone metastases from solid tumours.\n\nDenosumab 60 mg solution for injection (Prolia) is given once every 6 months to treat osteoporosis in postmenopausal women at increased risk of fractures. It is also indicated for treatment of bone loss associated with hormone ablation in men with prostate cancer who are at high risk of fractures.\n\nOsteonecrosis of the jaw\n\nOsteonecrosis of the jaw (ONJ) is a well-known and common side effect in patients receiving denosumab 120 mg for cancer. Risk factors for ONJ include:  \n  \n  * smoking  \n  * old age  \n  * poor oral hygiene  \n  * invasive dental procedures (eg, tooth extractions, dental implants, oral surgery)  \n  * comorbidity (eg, dental disease, anaemia, coagulopathy, infection)  \n  * advanced cancer  \n  * previous treatment with bisphosphonates  \n  * concomitant treatments (eg, chemotherapy, antiangiogenic biologics, corticosteroids, radiotherapy to head and neck)  \n  \nIn clinical trials, ONJ incidence increased with duration of denosumab 120 mg exposure. The patient-year adjusted incidence of confirmed ONJ was 1.1% in the first year of treatment, 3.7% in the second year, and 4.6% per year thereafter. Patients with certain dental risk factors (eg, history of ONJ, unhealed oral surgery) were excluded from these trials.\n\nThere have been rare cases of ONJ in patients receiving denosumab 60 mg for osteoporosis in clinical practice. The most common risk factors were invasive dental procedures, history of bisphosphonate therapy, and being more than 65 years old.\n\nTo date, we have received 9 Yellow Card reports[[1][1]](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON452540#_ftn1) of ONJ in patients receiving denosumab 120 mg, 12 reports in patients receiving denosumab 60 mg, and 5 reports in patients receiving an unspecified dose of denosumab.\n\nBased on this evidence, the recommendations regarding the need for a dental examination and appropriate preventive dentistry before treatment have been updated as described below.\n\nHypocalcaemia\n\nDenosumab is also associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment (see [Drug Safety Update article from October 2012](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199560)). Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later. Therefore the recommendations for calcium monitoring have been updated as described below.\n\nTo date, we have received 23 Yellow Card reports1 of hypocalcaemia in patients receiving denosumab 120 mg, 37 reports in patients receiving denosumab 60 mg, and 6 reports in patients receiving an unspecified dose of denosumab.\n\nAdvice for healthcare professionals\n\nOsteonecrosis of the jaw\n\nThe following precautions are now recommended to reduce the risk of ONJ:\n\nDenosumab 120 mg (cancer indication)  \n  \n  * A dental examination and appropriate preventive dentistry before starting denosumab 120 mg are now recommended for all patients.  \n  * Do not start denosumab 120 mg in patients with a dental or jaw condition requiring surgery, or in patients who have not recovered following oral surgery.  \n  \nDenosumab 60 mg (osteoporosis indication)  \n  \n  * Check for ONJ risk factors before starting denosumab 60 mg. A dental examination and appropriate preventive dentistry are now recommended for patients with risk factors.  \n  \nTell all patients to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.\n\nHypocalcaemia\n\nCalcium levels should now be monitored as follows:\n\nDenosumab 120 mg (cancer indication)  \n  \n  * Check calcium levels:   \n    * before the first dose  \n    * within two weeks after the initial dose  \n    * if suspected symptoms of hypocalcaemia occur.  \n  \nConsider monitoring calcium levels more frequently in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance <30 ml/min).\n\nDenosumab 60 mg (osteoporosis indication)  \n  \n  * Check calcium levels:   \n    * before each dose  \n    * within two weeks after the initial dose in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance <30 ml/min)  \n    * if suspected symptoms of hypocalcaemia occur.  \n  \nTell all patients to report symptoms of hypocalcaemia to their doctor (eg, muscle spasms, twitches, or cramps; numbness or tingling in the fingers, toes, or around the mouth).\n\nFurther information:\n\nLetters to healthcare professionals sent in August 2014 – includes advice on ONJ and hypocalcaemia that was previously in the summary of product characteristics and has not been changed, as well as the new advice above\n\n[ASSET_TAG](#ASSET0)\n\n[ASSET_TAG](#ASSET1)\n\nArticle citation: Drug Safety Update volume 8 issue 2, September 2014: A2\n\n  \n\n\n* * *\n\n[[1][1]](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON452540#_ftnref1)Yellow Card reports are reports of suspected adverse drug reactions (ADRs) submitted voluntarily by healthcare professionals and members of the public in the UK. The number of reports received should not be used to determine the incidence of an ADR. This is because neither the total number of ADRs occurring, nor the number of patients using the drug is known. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, and the extent of use of a particular drug, and may be stimulated by publicity about a drug.\n"
}